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Real-time quaking-induced conversion (RT-QuIC) has
been proposed as a sensitive diagnostic test for spo-
radic Creutzfeldt–Jakob disease; however, before this
assay can be introduced into clinical practice, its reliabil-
ity and reproducibility need to be demonstrated. Two
international ring trials were undertaken in which a set
of 25 cerebrospinal fluid samples were analyzed by a
total of 11 different centers using a range of recombi-
nant prion protein substrates and instrumentation. The
results show almost complete concordance between the
centers and demonstrate that RT-QuIC is a suitably reli-
able and robust technique for clinical practice.
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Creutzfeldt–Jakob disease (CJD) belongs to a familyof fatal neurodegenerative diseases known as trans-
missible spongiform encephalopathies (TSEs). TSEs are
characterized by the post-translational conformational
change of a normally expressed protein called prion pro-
tein (PrP) into a disease-associated form known as PrPSc.
Once formed, PrPSc can induce PrP to undergo a confor-
mational change and produce more PrPSc in a self-
propagating manner. The PrPSc aggregates, becomes pro-
tease resistant, and deposits throughout the brain, leading
to spongiform change and neuronal loss.
Patients with sporadic CJD (sCJD) present with a
rapidly progressing dementia, and death usually occurs
within 6 months. Current diagnostic criteria for sCJD
rely on clinical features, the results of electroencephalog-
raphy and magnetic resonance imaging, and the presence
of 14-3-3 protein in the cerebrospinal fluid (CSF).1,2
These tests are not specific for CJD, and none is able to
detect all forms of CJD.3,4
A new approach to the premortem diagnosis of
sCJD has been to exploit the ability of small amounts of
CSF PrPSc to convert native PrP into PrPSc in a newly
described protein aggregation assay known as real-time
quaking-induced conversion (RT-QuIC). This technique
uses recombinant PrP (rPrP) as a substrate, which is
induced to aggregate by the addition of CSF containing
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PrPSc. Thioflavin T (ThT) in the reaction binds to the
aggregated PrPSc, causing a change in the ThT emission
spectrum, enabling the reaction to be monitored in real
time.5,6
CSF RT-QuIC has been shown to be an accurate
diagnostic test for sCJD, with a high degree of sensitivity
(85–87%) and specificity (99–100%).7,8 An increasing
number of laboratories have established RT-QuIC analy-
sis, and more are interested in doing so. Before RT-
QuIC is fully accepted into clinical practice as a reliable
premortem diagnostic test, studies are required to ensure
that laboratories performing this assay using different
forms of recombinant PrP as a substrate and a variety of
instrumentation are producing comparable results.
This study reports the findings of 2 international
ring trials that were undertaken over a 2-year period.
The initial ring trial comprised European participants,
whereas the second ring trial was wider and included par-
ticipants from Australia, Canada, and Japan.
Materials and Methods
CSF Samples
CSF samples were provided by the National CJD Research &
Surveillance Unit, United Kingdom. These samples are stored
at &minus;80 8C, and consent was obtained from the next of
kin for their use in research (05/MRE00/67). CSF samples
were selected on the basis of having appropriate ethical consent
and sufficient volume to ensure that each participant had an
adequate volume of CSF for analysis. Each set of CSF samples
was sent to each laboratory on dry ice and was analyzed blind
to the final diagnosis. The performance of the RT-QuIC assay
was evaluated in an interlaboratory ring trial, where identical
CSF samples were analyzed by each of the participating labora-
tories. Using this approach, it may be possible to identify ana-
lytical procedures that affect overall assay performance.
Participants
A total of 11 laboratories participated in the ring trials: Depart-
ment of Pathology, University of Melbourne, Melbourne, Aus-
tralia (Aust); Department of Neurology, Antwerp University,
Antwerp, Belgium (Bel); Prion Laboratory Section, Public
Health Agency of Canada, Winnipeg, Canada (Can); Labora-
tory Investigations of Alzheimer’s Disease and Prion Diseases,
Pitie-Salpe^trie`re Hospital Group, Paris, France (Fra); Depart-
ment of Neurology, University Medical Center and German
Center for Neurodegenerative Diseases, G€ottingen, Germany
(Ger-Goet); Centre for Neuropathology and Prion Research,
Ludwig Maximilian University, Munich, Germany (Ger-Mun);
Department of Neurological Sciences, University of Bologna,
Bologna, Italy (It-Bol); Department of Neurodegenerative Dis-
ease, Carlo Besta Neurological Institute, Milan, Italy (It-Mil);
Department of Neurological Sciences, National Institute of
Health, Rome, Italy (It-Rome); Department of Molecular
Microbiology and Immunology, Nagasaki University, Nagasaki,
Japan (Jpn); and National CJD Research & Surveillance Unit,
University of Edinburgh, Edinburgh, UK (UK).
First Ring Trial
Seven laboratories (UK, It-Rome, It-Mil, It-Bol, Fra, Ger-Mun,
Bel) participated in the first ring trial, and each received 10
CSF samples sent on dry ice. Of these, 1 was from a patient
with neuropathologically confirmed sCJD, 4 were from patients
with probable sCJD, diagnosed according to the World Health
Organization criteria, 2 patients improved and the diagnosis of
sCJD was excluded on clinical grounds, 1 patient had a steroid-
responsive encephalopathy, 1 had no neuropathological evidence
of CJD at postmortem, and 1 had mixed Alzheimer disease and
vascular dementia at postmortem. The age of the patients
ranged from 48 to 86 years and included 5 females and 5
males. The disease duration of the patients with sCJD ranged
from 2 to 12 months, and the CSF samples were taken between
53% and 94% of the disease duration.
Second Ring Trial
Eleven laboratories (UK, It-Rome, It-Mil, It-Bol, Fra, Ger-
Mun, Ger-Goet, Jpn, Aust, Can, and Bel) participated in the
second ring trial, and each received 15 CSF samples sent on
dry ice. One laboratory analyzed the CSF samples twice using a
BMG LABTECH (Ortenberg, Germany) Optima and a BMG
LABTECH Omega. Of the 15 CSF samples, 5 were from
patients with probable sCJD, 3 were from patients with neuro-
pathologically confirmed sCJD, 1 patient improved and the
diagnosis of sCJD was excluded on clinical grounds, 1 had seiz-
ures, 1 had anti-immune encephalopathy, 1 had a psychiatric
disorder, 1 had Huntington disease, 1 had a non-CJD demen-
tia, and 1 had normal pressure hydrocephalus. The age of the
patients ranged from 55 to 87 years and included 6 females
and 9 males. The disease duration of the patients with sCJD
ranged from 1 to 26 months and the CSF samples were taken
between 57% and 90% of the disease duration.
Methodology
Each laboratory performed the RT-QuIC analysis using a stand-
ard 10mM phosphate buffer (pH7.4), 170mM NaCl (total
400mM including phosphate buffer) containing 0.1mg/ml rPrP,
10lM ThT, and 10mM ethylenediaminetetraacetic acid tetraso-
dium salt. However, a range of instrumentations, analytical con-
ditions, and types of rPrP were used (Table 1). Most laborato-
ries used either a BMG LABTECH Optima or a BMG
LABTECH Omega, whereas 1 laboratory used a Tecan Infinite
F200PRO (Tecan Group, M€annedorf, Switzerland). Nine labo-
ratories used hamster full-length (23–231) rPrP (supplied by
Bristol Institute of Blood Sciences, Bristol, UK),8,9 2 used
human full-length (23–231) rPrP (produced in-house),7 and 1
used a hamster–sheep chimeric rPrP (hamster 14–126 residues
followed by sheep residues 141-234, produced according to pre-
viously reported conditions).5
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Results
The results of the ring trials are given in Tables 2 and 3.
In the first ring trial 6, of 7 laboratories obtained positive
RT-QuIC responses in the CSF samples from all 5 sCJD
cases; the remaining laboratory obtained positive RT-
QuIC responses in the CSF of 4 of the 5 sCJD cases. A
negative RT-QuIC result was obtained in the CSF of 1
sCJD case, which had a disease duration of 12 months.
This laboratory was using a BMG LABTECH Optima
instrument, with full-length hamster rPrP as substrate
and 30 ml of CSF. These conditions were similar to other
laboratories in the study that obtained positive results for
this particular CSF sample. A limited volume of CSF
was sent to each laboratory, and this meant that repeating
the analysis of this particular CSF by the individual labo-
ratory was not possible.
None of the laboratories obtained positive RT-
QuIC responses in any of the 5 CSF samples from
patients without sCJD. Four of these laboratories used a
BMG LABTECH Optima, and the remaining 3 used a
BMG LABTECH Omega. However, all the laboratories
used the same full-length hamster rPrP.
The second ring trial included a larger number of
laboratories with a wider geographical distribution and
included a wider range of instrumentation and type of
rPrP. Despite this, the results showed complete concord-
ance (see Table 3). Of the 11 laboratories that partici-
pated in this ring trial, 11 obtained positive RT-QuIC
TABLE 1. Instrumentation, Analytical Conditions, and Source of Recombinant PrP Used by Each of the Partici-
pating Centers
Group Reader Recombinant
PrP
CSF
Volume
Shake
Conditions
Temp,
8C
Criteria for Positive Result
UK Omega Omega Ham FL 30 ml 900rpm 90 s
shake/30 s rest
42 Mean of 2 highest replicates
of 4> 24,000rfu at 90 h
UK Optima Optima Ham FL 30 ml 600rpm 60 s
shake/60 s rest
42 Mean of 2 highest replicates
of 4> 10,000rfu at 90 h
Germany
(Munich)
Optima Ham FL 30 ml 600rpm 60 s
shake/60 s rest
42 Mean of 2 highest replicates
of 4> 10,000rfu at 90 h
Germany
(G€ottingen)
Optima Ham-Sh
chimeric
15 ml 600rpm 60 s
shake/60 s rest
42 Mean of 2 highest replicates
of 4> 10,000rfu at 80 h
Italy (Bologna) Optima Ham FL 15 ml 600rpm 60 s
shake/60 s rest
42 Mean of 2 highest replicates
of 4> 6,000rfu at 90 h
Italy (Milan) Optima Ham FL 30 ml 600rpm 60 s
shake/60 s rest
42 Mean of 2 highest replicates
of 4> 10,000rfu at 90 h
Italy (Rome) Omega Ham FL 30 ml 900rpm 90 s
shake/30 s rest
42 Mean of 2 highest replicates
of 4> 32,000rfu at 90 h
France Omega Ham FL 30 ml 900rpm 90 s
shake/30 s rest
42 Mean of 2 highest replicates
of 4> 34,345rfu at 90 h
Belgium Omega Ham FL 20 ml 900rpm 90 s
shake/30 s rest
42 Mean of 2 highest replicates
of 4> 20,000rfu at 90 h
Canada Omega Ham FL 30 ml 900rpm 90 s
shake/30 s rest
42 Mean of 2 highest replicates
of 4> twice baseline
reading at 90 h
Japan Tecan Hum FL 5 ml Max 30 s
shake/30 s rest
37 At least 2 of 6 replicates
> 400rfu at 90 h
Australia Optima Hum FL 5 ml 750rpm 30 s
shake/30 s resta
37 Mean of 2 highest replicates
of 4> 70% of baseline
rfu reading at 90 h
aShaking performed in a Thermomixer Comfort (Eppendorf, Hamburg, Germany) before being read in an Optima instrument.
CSF5 cerebrospinal fluid; Ham FL5 hamster full-length PrP (23–231)8,9; Ham-Sh chimeric5 hamster residues14–128:sheep141–
234
5; Hum FL5 human full-length (23–231)—codon 129M6; PrP5 prion protein; rfu5 relative fluorescence units.
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responses in all 8 CSF samples from sCJD patients. All
11 laboratories obtained a positive RT-QuIC response in
the CSF from the sCJD patient, with a disease duration
of 26 months. This CSF sample was taken 21 months
after the onset of symptoms. The laboratory that failed
to obtain a positive CSF RT-QuIC response in an sCJD
case in the first ring trial correctly identified all sCJD
cases in the second ring trial. None of the analytical
parameters had been changed by the laboratory in ques-
tion. Importantly, the laboratory that used a Tecan Infi-
nite shaker with a human rPrP as a substrate also cor-
rectly identified all sCJD cases. One laboratory analyzed
the ring trial CSF samples using both the BMG LAB-
TECH Optima or a BMG LABTECH Omega and
obtained similar results using both instruments despite
having different cutoff criteria. None of the laboratories
obtained positive RT-QuIC responses in CSF samples
from patients with non-CJD disorders.
Discussion
In the first ring trial, 6 of 7 laboratories correctly identi-
fied all sCJD cases; however, 1 laboratory obtained a
negative CSF RT-QuIC result from an sCJD patient
with a disease duration of 12 months. It has been
reported that CSF samples from sCJD patients with lon-
ger disease durations may have lower seeding efficiency10;
however, this effect was not seen in the second ring trial,
where the CSF from an sCJD patient with a disease
duration of 26 months was identified by RT-QuIC by all
laboratories. All the laboratories that participated in the
first ring trial used the same source and type of rPrP and
either Optima or Omega BMG LABTECH instrumenta-
tion, and demonstrated high levels of accuracy and agree-
ment between laboratories.
The second ring trial took place 18 months later
and was expanded to include other European laboratories
and participants from Australia, Canada, and Japan.
Some of the additional laboratories used alternative types
of rPrP and other forms of instrumentation. This enabled
a more rigorous assessment of the robustness and trans-
ferability of the RT-QuIC technique.
All 11 laboratories accurately identified the 8 CSF
samples from sCJD patients, and none detected a posi-
tive RT-QuIC in any of the non-CJD cases. The agree-
ment between laboratories using different rPrP as a sub-
strate and different forms of instrumentation is
encouraging. The accuracy of the results obtained was
identical for each of the rPrP substrates used. From this
TABLE 2. Results for the First Ring Trial with 7 Participating Centers
CSF
ID
Diagnosis Gender
(age, yr)
Disease
Duration,
mo
Timing of LP
as % of
Disease
Duration
Laboratories
Reporting
Positive
RT-QuIC, No.
Concordance,
%
1 Patient improved M (68) Still alive n/a 0/7 100
2 Steroid-responsive
encephalopathy
M (69) Still alive n/a 0/7 100
3 Neuropathological
evidence of mixed AD
and vascular dementia
M (86) 3 92 0/7 100
4 Psychiatric disorder M (63) Still alive n/a 0/7 100
5 Patient improved F (74) Still alive n/a 0/7 100
6 Definite sCJD—codon
129MM; PrP type: 1
F (75) 3 83 7/7 100
7 Probable sCJD F (48) 2 77 7/7 100
8 Probable sCJD—codon
129MM
F (64) 12 94 6/7 83
9 Probable sCJD F (72) 4 76 7/7 100
10 Probable sCJD—codon
129 VV
M (69) 4 53 7/7 100
AD5Alzheimer disease; CSF5 cerebrospinal fluid; F5 female; LP5 lumbar puncture; M5male; n/a5 applicable; PrP5 prion
protein; RT-QuIC5 real-time quaking-induced conversion; sCJD5 sporadic Creutzfeldt–Jakob disease.
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limited number of CSF samples, we have achieved an
overall sensitivity of between 85.7% and 100% and a
specificity of 100%. This compares well with a previous
intralaboratory study, which had fewer participants and
reported a sensitivity of 85% and a specificity of 99%.10
The complete concordance between laboratories demon-
strates that CSF RT-QuIC is adaptable to different labo-
ratory instrumentation and different types of rPrP. The
high level of accuracy and agreement between laborato-
ries using CSF RT-QuIC is supportive of this technique
being introduced into clinical practice.
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TABLE 3. Results from the Second Ring Trial with 11 Participating Laboratories
CSF
ID
Diagnosis Gender
(age, yr)
Disease
Duration,
mo
Timing of
LP as % of
Disease
Duration
Laboratoriesa
Reporting
Positive
RT-QuIC, No.
Concordance,
%
1 Patient improved F (87) Still alive — 0/12 100
2 Seizures M (56) — — 0/12 100
3 Autoimmune encephalitis F (82) Still alive — 0/12 100
4 Psychiatric disorder M (55) Still alive — 0/12 100
5 Huntington disease F (67) Still alive — 0/12 100
6 Mixed vascular and
Alzheimer dementia
M (80) Still alive — 0/12 100
7 Normal pressure
hydrocephalus
M (78) Still alive — 0/12 100
8 Definite sCJD F (63) 6 90 12/12 100
9 Definite sCJD—codon
129MM; PrPSc type 1
M (73) 1 71 12/12 100
10 Definite sCJD—codon
129MM
M (66) 5 57 12/12 100
11 Probable sCJD M (84) No data — 12/12 100
12 Probable sCJD M (66) 3 83 12/12 100
13 Probable sCJD M (69) 3 80 12/12 100
14 Probable sCJD F (65) 26 83 12/12 100
15 Probable sCJD F (67) 8 88 12/12 100
aThe UK laboratory submitted 2 sets of results using 2 sets of instruments: BMG LABTECH Omega and BMG LABTECH
Optima.
CSF5 cerebrospinal fluid; F5 female; LP5 lumbar puncture; M5male; PrPSc5 disease-associated form of prion protein; RT-
QuIC5 real-time quaking-induced conversion; sCJD5 sporadic Creutzfeldt–Jakob disease.
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